SG Americas Securities LLC Cuts Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

SG Americas Securities LLC reduced its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 45.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,025 shares of the company’s stock after selling 6,694 shares during the quarter. SG Americas Securities LLC’s holdings in Kymera Therapeutics were worth $323,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of KYMR. Massachusetts Financial Services Co. MA boosted its position in Kymera Therapeutics by 11.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock worth $21,458,000 after purchasing an additional 47,507 shares in the last quarter. Eventide Asset Management LLC raised its stake in shares of Kymera Therapeutics by 9.9% during the 3rd quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock worth $24,039,000 after buying an additional 45,803 shares during the period. Intech Investment Management LLC purchased a new position in shares of Kymera Therapeutics during the 3rd quarter valued at approximately $650,000. JPMorgan Chase & Co. lifted its position in shares of Kymera Therapeutics by 212.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock valued at $6,649,000 after buying an additional 95,547 shares in the last quarter. Finally, Natixis Advisors LLC acquired a new stake in Kymera Therapeutics in the 3rd quarter valued at $681,000.

Insider Activity

In related news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the transaction, the insider now directly owns 54,826 shares in the company, valued at approximately $2,288,985.50. This represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 15.82% of the company’s stock.

Analysts Set New Price Targets

KYMR has been the topic of several recent analyst reports. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Morgan Stanley raised their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. UBS Group cut their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Guggenheim increased their target price on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, November 1st. Finally, Stephens reaffirmed an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and an average price target of $55.06.

Kymera Therapeutics Price Performance

Shares of KYMR stock opened at $38.73 on Wednesday. The company has a market capitalization of $2.51 billion, a PE ratio of -16.55 and a beta of 2.18. The firm’s 50-day moving average is $42.12 and its two-hundred day moving average is $44.65. Kymera Therapeutics, Inc. has a 12 month low of $29.24 and a 12 month high of $53.27.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.